[Form 4] Fulgent Genetics, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Kim Paul, Chief Financial Officer and Treasurer of Fulgent Genetics, Inc. (FLGT), reported a change in beneficial ownership. On 08/26/2025 the reporting person had 1,166 shares of common stock disposed of at a price of $21.47 per share, leaving 337,992 shares beneficially owned after the transaction. The filing explains those shares were withheld to satisfy tax-withholding obligations tied to restricted stock units that vested from a grant dated 02/26/2024 (originally reported 02/28/2024). The Form 4 is signed by Paul Kim on 08/28/2025.

Positive

• Transaction disclosed with explanation: The Form 4 explicitly states the shares were withheld to satisfy tax withholding on vested RSUs.
• Post-transaction ownership shown: The filing reports 337,992 shares beneficially owned after the withholding.
• Officer status identified: Reporting person is clearly listed as CFO and Treasurer, improving transparency.

Negative

• Reduction in holdings: 1,166 shares were disposed of (withheld), reducing the reporting person's share count.
• Limited context on materiality: The filing does not provide information to determine whether the disposition is material relative to total holdings or recent trading activity.

Insights

Financial Analyst

TL;DR: Officer share withholding for taxes after RSU vesting; small disposition and routine disclosure, no indication of trading for liquidity.

The Form 4 shows a single non-derivative disposition of 1,166 shares at $21.47 resulting from tax withholding upon RSU vesting. This is a routine administrative transaction that preserves post-vesting ownership of 337,992 shares. There are no additional purchases, open-market sales, or derivative exercises reported that would suggest a change in compensation structure or a material shift in insider conviction.

Corporate Governance Expert

TL;DR: Proper Section 16 disclosure of RSU tax withholding; filing appears compliant and timely.

The report identifies the reporting person as an officer (CFO and Treasurer) and discloses the withholding to meet tax obligations tied to an earlier RSU grant. The transaction is documented with explanation and a dated signature, consistent with required insider reporting practices. No governance red flags (e.g., undisclosed related-party transfers) are present in the content provided.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kim Paul

(Last) (First) (Middle)

C/O FULGENT GENETICS, INC.

4399 SANTA ANITA AVENUE

(Street)

EL MONTE CA 91731

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Fulgent Genetics, Inc. [ FLGT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CFO and Treasurer

3. Date of Earliest Transaction (Month/Day/Year)
08/26/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/26/2025		F		1,166(1)	D	$21.47	337,992	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 26, 2024, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on February 28, 2024.

	/s/ Paul Kim	08/28/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transaction did Kim Paul (FLGT) report on Form 4?

The filing reports a disposition of 1,166 shares of Fulgent Genetics common stock on 08/26/2025 at a price of $21.47 per share.

Why were the 1,166 shares disposed of according to the Form 4?

The shares were withheld to satisfy tax withholding obligations resulting from the vesting of restricted stock units granted on 02/26/2024.

How many Fulgent Genetics shares does the reporting person own after the transaction?

After the transaction the reporting person beneficially owns 337,992 shares.

What is the reporting person’s role at Fulgent Genetics?

The reporting person, Kim Paul, is listed as CFO and Treasurer of Fulgent Genetics, Inc.

When was the Form 4 signed?

The Form 4 is signed by /s/ Paul Kim on 08/28/2025.